0 participants
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-09-29
- Start Date:
- 2021-03-01
- Completion:
- 2021-09-02
Conditions
- Advanced Neuroendocrine Neoplasm
- Carcinoid Syndrome
Interventions
- BIOLOGICAL
- DRUG
No Results Yet